open access

Vol 73, No 6 (2022)
Brief communication
Submitted: 2022-04-02
Accepted: 2022-07-07
Published online: 2022-12-12
Get Citation

Serum IL-38 levels in patients with type 2 diabetes mellitus

Tingqi Zhao1, Mengxi Yu1, Mingcai Li12, Yan Li12
·
Pubmed: 36519654
·
Endokrynol Pol 2022;73(6):988-989.
Affiliations
  1. Department of Endocrinology, The Affiliated Hospital of Medical School, Ningbo University, Ningbo, China
  2. Department of Immunology, Zhejiang Key Laboratory of Pathophysiology, Ningbo University School of Medicine, Ningbo, China

open access

Vol 73, No 6 (2022)
Short communication
Submitted: 2022-04-02
Accepted: 2022-07-07
Published online: 2022-12-12

Abstract

Introduction: Interleukin 38 (IL-38) is a new member of the IL-1 family, and it has anti-inflammatory activity. However, its role in type 2 diabetes mellitus (T2DM) has not been reported.

Material and methods: The study included 40 T2DM patients and 42 healthy control subjects. The anthropometric and biochemical measurements were performed using an automatic biochemical analyser, high-performance liquid chromatography, and electrochemiluminescence immunoassay. Circulating IL-38 levels were determined by enzyme-linked immunosorbent assay.

Results: Serum IL-38 levels in T2DM patients were significantly lower than those in controls. Correlation analysis showed that serum IL-38 was negatively correlated with systolic blood pressure and interleukin 17 (IL-17).

Conclusions: The results suggest that IL-38 may be a new biomarker of T2DM.

Abstract

Introduction: Interleukin 38 (IL-38) is a new member of the IL-1 family, and it has anti-inflammatory activity. However, its role in type 2 diabetes mellitus (T2DM) has not been reported.

Material and methods: The study included 40 T2DM patients and 42 healthy control subjects. The anthropometric and biochemical measurements were performed using an automatic biochemical analyser, high-performance liquid chromatography, and electrochemiluminescence immunoassay. Circulating IL-38 levels were determined by enzyme-linked immunosorbent assay.

Results: Serum IL-38 levels in T2DM patients were significantly lower than those in controls. Correlation analysis showed that serum IL-38 was negatively correlated with systolic blood pressure and interleukin 17 (IL-17).

Conclusions: The results suggest that IL-38 may be a new biomarker of T2DM.

Get Citation

Keywords

type 2 diabetes mellitus; interleukin 38; interleukin 17

Supp./Additional Files (1)
Supplementary Files
Download
81KB
About this article
Title

Serum IL-38 levels in patients with type 2 diabetes mellitus

Journal

Endokrynologia Polska

Issue

Vol 73, No 6 (2022)

Article type

Brief communication

Pages

988-989

Published online

2022-12-12

Page views

3554

Article views/downloads

408

DOI

10.5603/EP.a2022.0089

Pubmed

36519654

Bibliographic record

Endokrynol Pol 2022;73(6):988-989.

Keywords

type 2 diabetes mellitus
interleukin 38
interleukin 17

Authors

Tingqi Zhao
Mengxi Yu
Mingcai Li
Yan Li

References (2)
  1. Yuan X, Peng X, Li Y, et al. Role of IL-38 and its related cytokines in inflammation. Mediators Inflamm. 2015; 2015: 807976.
  2. Yu Z, Liu J, Zhang R, et al. IL-37 and 38 signalling in gestational diabetes. J Reprod Immunol. 2017; 124: 8–14.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl